The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 2 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 2, 10 January 2008
Rapid communications
Outbreak of serogroup C meningococcal disease in Veneto region, Italy
  1. Servizio Sanità Pubblica e Screening, Direzione Regionale Prevenzione, Venezia, Italy
  2. Regional Surveillance System for Meningitis Control, University of Padua, Padua, Italy
  3. Direzione Sanitaria Azienda Ulss 7, Pieve di Soligo, Italy
  4. Dipartimento di Prevenzione, Azienda Ulss 9, Treviso, Italy
  5. Dipartimento di Prevenzione Azienda Ulss 8, Asolo, Italy
  6. Dipartimento di Prevenzione Azienda Ulss 7, Pieve di Soligo, Italy

Citation style for this article: Ferro A, Baldo V, Cinquetti S, Corziali P, Gallo G, Lustro G, Paludetti P, Menegon T, Baldovin T, Palù G, Trivello R. Outbreak of serogroup C meningococcal disease in Veneto region, Italy. Euro Surveill. 2008;13(2):pii=8008. Available online:


Meningococcal infections occur worldwide as endemic disease; there have also been outbreaks in Europe and in the Americas in the last 30 years but they have not reached the high incidence levels of epidemics in other parts of the world [1].

Neisseria meningitidis causes rapid-onset bacteremia, primarily affecting children and young adults. Most of those exposed do not become ill but are temporarily asymptomatic carriers (about 10%) with peak carriage rates among people aged 15 to 30 years [2].

In Italy, the incidence of N. meningitis infections is one of the lowest in Europe. Most are sporadic cases, but outbreaks sometimes occur, often in relation to serogroup C strains.

Figure 1 shows the rapid increase in the number of N. meningitidis serogroup C cases since 2000, with a peak in 2005 and a subsequent decline in 2006 and in the early months of 2007 [3].

Outbreak description

Between 13 and 15 December 2007, seven cases of meningitis caused by N. meningitidis were reported in the Treviso area, region of Veneto in north-eastern Italy. Three of them were fatal. Serotyping at the local microbiology laboratories (in Treviso, Montebelluna and Pieve di Soligo) has demonstrated the presence of meningococci serogroup C in six cases, while the analysis is still underway for the seventh case. The reference microbiology laboratory in Padua confirmed that the meningococci isolated were genetically related.

The mean age of the cases was 23 years (range 15-33 years). The epidemiological investigation revealed that all of them had attended the same places in the Treviso area (bars, restaurants, discos) between 8 and 9 December.

On the basis of this investigation, on 15 and 16 December, 600 people considered at risk of contact because they had frequented the same places as the cases, received chemoprophylaxis at the Hygiene and Public Health departments and first-aid facilities were set up to deal with the situation.

About 80 people with suspected symptoms of the disease were admitted to hospital as a precautionary measure, but the infection was not confirmed and all were discharged.

The outbreak raised considerable concern among the population of the Veneto region, increasing the demand for treatment (chemoprophylaxis and vaccination).

In total, the Veneto Surveillance System for Meningitis Control registered 14 cases of Neisseria meningitidis serogroup C infection in 2007, bringing the annual incidence rate in the Veneto Region to 0.3 per 100,000 population (Table 1, Figure 2).

Subsequently, two more cases were reported in the region of Veneto, on 20 December (Treviso area) and 4 January (Venice area) respectively, bringing the total number of cases in this outbreak to nine.

Management of the outbreak in the Treviso area

The management of the current outbreak in Treviso was assessed by a commission comprising members of the Prevention Departments of the areas involved, the Veneto Surveillance System for Meningitis Control and the Istituto Superiore di Sanità (ISS), and by consulting experts from the European Centre for Disease Prevention and Control (ECDC) and the Global Outbreak Alert and Response Network (GOARN) special task force.

The main control measures adopted in the management of serogroup C meningococcal outbreak are chemoprophylaxis for people at risk of infection and vaccination

Chemoprophylaxis is recommended only to those in close contact with the infected patients, including: a) members of the patient's household; b) contacts at day care centers; and c) people directly exposed to the patient's oral secretions (e.g. through mouth-to-mouth resuscitation or kissing). Giving chemoprophylaxis to people who have not been in close contact with the infected patients has not proved effective in preventing community outbreak-associated cases and is not usually recommended [4].

The first step was to determine the target group to consider as close contacts requiring chemoprophylaxis. Considering the epidemiological aspects of the epidemic cluster (number of cases, strain virulence and outbreak localization), it was decided that chemoprophylaxis should be administered to all subjects who attended the same place as the cases.

The vaccines currently available in Italy are the meningococcal C conjugated vaccine and the meningococcal polysaccharide vaccine (A, C, Y and W135).
In the Veneto Region, vaccination is offered free of charge for 1-year-olds and 15-year-olds, based on a plan implemented two years ago, with a coverage of 77% and 50% respectively (data as of 30 September 2007).

In response to the outbreak, young people of similar age as the cases (15-29 years) in the Treviso area affected by the outbreak were vaccinated with a single dose of meningococcal C conjugated vaccine to achieve a specific immunization state within two weeks. The vaccine also has a significant effect on healthy carriers, thus reducing the transmission of the microorganism [5].

During January 2008, the need to extend the vaccination plan to other areas in the region and other birth cohorts will be assessed in order to quickly increase the vaccination coverage among young people at greater risk of the disease.

Educating the general population as well as physicians and other health-care workers about meningococcal disease has also been considered an important element of the management of this outbreak.



  1. Manchanda V, Gupta S et al. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. IJMM 2006; 24: 7-19.
  2. Reinijes R, Kistemann T et al. Detection and response to a meningococcal disease outbreak following a youth football tournament with teams from four European counties. Int.J. Hyg.Environ. Health 2002; 205, 291-6.
  3. National Surveillance System at Istituto Superiore di Sanità (ISS), data available at:
  4. CDC. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreak: recommendations of the advisory committee on immunization practices (ACIP) MMWR 1997; 46: 13-21.
  5. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 10th ed. Washington DC: Public Health Foundation, 2007.


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.